• In February 2026, PTC Therapeutics reported fourth-quarter 2025 results showing revenue of US$164.68 million versus US$213.17 million a year earlier, alongside a wider quarterly net loss, while full-year 2025 revenue rose to US$1.73 billion and net income reached US$682.64 million compared with a net loss previously.
• A key development was PTC’s withdrawal of its Translarna NDA resubmission for nonsense mutation Duchenne muscular dystrophy in the U.S. after FDA feedback, introducing fresh uncertainty around one of its rare disease assets even as overall 2025 revenues surpassed prior guidance.
• We’ll now examine how the Translarna NDA withdrawal and mixed quarterly earnings reshape PTC Therapeutics’ investment narrative and risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

PTC Therapeutics Investment Narrative Recap

To own PTC Therapeutics today, you need to be comfortable with a rare disease story that is increasingly centered on Sephience and a concentrated portfolio, while accepting regulatory and earnings volatility. The Translarna NDA withdrawal heightens near term uncertainty around one of its legacy assets, but the key short term catalyst remains the global rollout and uptake of Sephience, with the main risk being how dependent PTC still is on a handful of products and ongoing regulatory decisions.

The most relevant recent announcement is PTC’s fourth quarter and full year 2025 earnings release, which paired a weak quarter with a profitable year and US$1,730.66 million in revenue. That backdrop matters for the Translarna setback because it shows the company currently has earnings support from a broader base, even as Translarna’s U.S. and European regulatory challenges keep the overall revenue mix and future cash generation exposed to policy and approval outcomes.

Yet despite strong 2025 revenue, investors should be aware that concentrated product risk and shifting Translarna access could still...

PTC Therapeutics’ narrative projects $1.3 billion revenue and $55.4 million earnings by 2028.

Uncover how PTC Therapeutics' forecasts yield a $87.93 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were banking on about US$1.3 billion of revenue and roughly US$205 million of earnings by 2028, but if Translarna’s setbacks persist while the rare disease portfolio stays concentrated, you should expect those bullish narratives and the more cautious consensus view to evolve in different ways as new data and regulatory updates arrive.

Explore 3 other fair value estimates on PTC Therapeutics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PTC Therapeutics research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free PTC Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PTC Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.